AVTR:NYE-Avantor Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 21.48

Change

+0.12 (+0.56)%

Market Cap

USD 14.44B

Volume

2.06M

Analyst Target

USD 23.81
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.37 (+0.16%)

USD 66.03B
ALC Alcon AG

-0.65 (-0.75%)

USD 41.92B
RMD ResMed Inc

-0.70 (-0.30%)

USD 34.83B
BAX Baxter International Inc

-0.10 (-0.34%)

USD 16.24B
ATR AptarGroup Inc

-0.70 (-0.44%)

USD 11.39B
TFX Teleflex Incorporated

-0.63 (-0.35%)

USD 8.27B
BLCO Bausch + Lomb Corp

-0.17 (-0.94%)

USD 7.27B
STVN Stevanato Group SpA

-0.13 (-0.60%)

USD 6.36B
WRBY Warby Parker Inc

-0.61 (-2.44%)

USD 2.84B
INFU InfuSystems Holdings Inc

-0.02 (-0.25%)

USD 0.18B

ETFs Containing AVTR

COPP Sprott Copper Miners ETF 10.10 % 0.00 %

-0.24 (-0.31%)

N/A
CEBS:XETRA iShares Copper Miners UCI.. 5.23 % 0.00 %

-0.01 (-0.31%)

USD 0.04B
COPG:LSE Global X Copper Miners UC.. 4.71 % 0.00 %

-0.13 (-0.31%)

USD 0.15B
WIRE:AU Global X Copper Miners ET.. 4.68 % 0.00 %

+0.04 (+-0.31%)

N/A
4COP:XETRA Global X Copper Miners UC.. 4.67 % 0.00 %

+0.16 (+-0.31%)

USD 0.09B
COPX:SW Global X Copper Miners UC.. 4.56 % 0.00 %

+0.19 (+-0.31%)

N/A
D6AT:XETRA Global X Disruptive Mater.. 4.46 % 0.00 %

+0.04 (+-0.31%)

N/A
COPX:LSE Global X Copper Miners UC.. 4.31 % 0.00 %

-0.18 (-0.31%)

N/A
COPA Themes Copper Miners ETF 3.97 % 0.00 %

-0.07 (-0.31%)

USD 0.69M
GMTL:AU Global X Green Metal Mine.. 3.73 % 0.00 %

N/A

N/A
SETM:LSE 3.14 % 0.00 %

N/A

N/A
BSJO Invesco BulletShares 2024.. 0.00 % 0.42 %

N/A

N/A
COPX Global X Copper Miners ET.. 0.00 % 0.65 %

-0.23 (-0.31%)

USD 2.63B
HYDW Xtrackers Low Beta High Y.. 0.00 % 0.25 %

-0.09 (-0.31%)

USD 0.31B
PQIN 0.00 % 0.00 %

N/A

N/A
IESZ:LSE 0.00 % 0.00 %

N/A

N/A
EMOM:PA BNP Paribas Easy ESG Equi.. 0.00 % 0.00 %

+0.04 (+-0.31%)

USD 3.00M
MOED:PA BNP Paribas Easy - Equity.. 0.00 % 0.00 %

+0.02 (+-0.31%)

USD 0.82M
EXV6:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
EXV6:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

+0.52 (+-0.31%)

USD 0.37B
MOED:XETRA BNP Paribas Easy - Equity.. 0.00 % 0.00 %

+1.12 (+-0.31%)

USD 2.20M
MOEU:XETRA BNP Paribas Easy ESG Equi.. 0.00 % 0.00 %

+1.32 (+-0.31%)

USD 2.20M
CRIT Optica Rare Earths & Crit.. 0.00 % 0.00 %

-0.15 (-0.31%)

USD 3.50M
BRHY BlackRock High Yield ETF 0.00 % 0.00 %

-0.01 (-0.31%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.91% 47% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.91% 42% F 19% F
Trailing 12 Months  
Capital Gain -6.93% 42% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.93% 42% F 18% F
Trailing 5 Years  
Capital Gain 17.96% 69% C- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.96% 63% D 45% F
Average Annual (5 Year Horizon)  
Capital Gain 14.67% 74% C 74% C
Dividend Return 14.67% 74% C 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.51% 42% F 20% F
Risk Adjusted Return 30.87% 79% B- 45% F
Market Capitalization 14.44B 71% C- 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector